Melinda Pryor
Overview
Explore the profile of Melinda Pryor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
516
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamilton S, Zhu M, Cloney-Clark S, Mayes P, Fenner J, Cui L, et al.
J Virol Methods
. 2024 Apr;
327:114945.
PMID: 38649070
As variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, assessment of vaccine immunogenicity remains a critical factor to support continued vaccination. To this end, an in...
2.
Kulkarni P, Gunale B, Kohli S, Lalwani S, Tripathy S, Kar S, et al.
Sci Rep
. 2023 Oct;
13(1):16579.
PMID: 37789040
Due to waning immunity following primary immunization with COVID-19 vaccines, booster doses may be required. The present study assessed a heterologous booster of SII-NVX-CoV2373 (spike protein vaccine) in adults primed...
3.
Gunale B, Kapse D, Kar S, Bavdekar A, Kohli S, Lalwani S, et al.
JAMA Pediatr
. 2023 Jul;
PMID: 37523166
Importance: The recombinant COVID-19 vaccine NVX-CoV2373 has demonstrated efficacy of approximately 90% in adults; however, its safety and efficacy in children is unknown. Objective: To assess the noninferiority of SII-NVX-CoV2373...
4.
Kulkarni P, Kadam A, Godbole S, Bhatt V, Raut A, Kohli S, et al.
Lancet Reg Health Southeast Asia
. 2023 Jan;
10:100139.
PMID: 36647543
Background: NVX-CoV2373, a Covid-19 vaccine was developed in the USA with ∼90% efficacy. The same vaccine is manufactured in India after technology transfer (called as SII-NVX-CoV2373), was evaluated in this...
5.
Evans T, Bussey L, Eagling-Vose E, Rutkowski K, Ellis C, Argent C, et al.
Lancet Infect Dis
. 2022 Mar;
22(6):857-866.
PMID: 35305317
Background: In animal, epidemiological, and human challenge studies, a pre-existing T-cell response to internal proteins of influenza A has been associated with improved virological and disease outcomes. The aim of...
6.
Forster A, Witham K, Depelsenaire A, Veitch M, Wells J, Wheatley A, et al.
PLoS Med
. 2020 Mar;
17(3):e1003024.
PMID: 32181756
Background: The Vaxxas high-density microarray patch (HD-MAP) consists of a high density of microprojections coated with vaccine for delivery into the skin. Microarray patches (MAPs) offer the possibility of improved...
7.
Fernando G, Hickling J, Jayashi Flores C, Griffin P, Anderson C, Skinner S, et al.
Vaccine
. 2018 May;
36(26):3779-3788.
PMID: 29779922
Background: Injection using needle and syringe (N&S) is the most widely used method for vaccination, but requires trained healthcare workers. Fear of needles, risk of needle-stick injury, and the need...
8.
Draffan A, Frey B, Fraser B, Pool B, Gannon C, Tyndall E, et al.
Bioorg Med Chem Lett
. 2014 Oct;
24(21):4984-8.
PMID: 25288185
Previous investigations identified 2'-C-Me-branched ribo-C-nucleoside adenosine analogues, 1, which contains a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base, and 2, which contains an imidazo[2,1-f][1,2,4]triazin-4-amine heterocyclic base as two compounds with promising anti-HCV in vitro...
9.
Draffan A, Frey B, Pool B, Gannon C, Tyndall E, Lilly M, et al.
ACS Med Chem Lett
. 2014 Jun;
5(6):679-84.
PMID: 24944743
Nucleoside analogues have long been recognized as prospects for the discovery of direct acting antivirals (DAAs) to treat hepatitis C virus because they have generally exhibited cross-genotype activity and a...
10.
Bart Tarbet E, Hamilton S, Vollmer A, Luttick A, Ng W, Pryor M, et al.
J Antimicrob Chemother
. 2014 Apr;
69(8):2164-74.
PMID: 24777908
Objectives: Emerging drug resistance to antiviral therapies is an increasing challenge for the treatment of influenza virus infections. One new antiviral compound, BTA938, a dimeric derivative of the viral neuraminidase...